Active Ingredient History
Methylnaltrexone, is a peripherally acting μ-opioid receptor antagonist that acts on the gastrointestinal tract to inhibit the opioid-induced decrease in gastric motility and transit time. It is used to treat opiate-induced constipation in adults with chronic non-cancer pain and in adults with advanced illness who are receiving palliative care. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adult (Phase 1)
Constipation ()
Coronary Artery Disease (Phase 4)
Enteral Nutrition (Phase 3)
Esophageal Diseases (Phase 4)
Gastroparesis (Phase 2)
General Surgery (Phase 3)
Healthy Volunteers (Phase 2)
Ileus (Phase 3)
Intestinal Diseases (Phase 2)
Intestinal Obstruction (Phase 1)
Kidney Failure, Chronic (Phase 1)
Liver Diseases (Phase 1)
Methadone (Phase 1)
Morphine (Phase 4)
Naltrexone (Phase 4)
Neoplasms (Phase 2)
Opioid-Induced Constipation (Phase 4)
Opioid-Related Disorders (Phase 2)
Pancreatic Neoplasms (Phase 3)
Pancreatitis (Phase 2/Phase 3)
Pharyngeal Diseases (Phase 4)
Postoperative Complications (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 4)
ST Elevation Myocardial Infarction (Phase 4)
Stomach Diseases (Phase 4)
Swallows (Phase 4)
Terminally Ill (Phase 3)
Ticagrelor (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue